Clexio Biosciences Ltd.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Clexio Biosciences is a CNS-first clinical stage company. We are dedicated to developing novel therapies for patients suffering from neurological and psychiatric conditions.

We have a broad and growing pipeline and are focused on the development of safe and effective treatments to address patients’ unmet needs in Major Depressive Disorder, Neuropathic Itch (pruritus) and Neuropathic Pain, Cluster Headache and Parkinson’s Disease.

One of our driving principles is to invent new therapeutic modalities and bring them quickly from an idea to Proof of Concept and then to full clinical development.

Our multidisciplinary team brings with them years of experience in the Pharmaceutical industry and encompasses end-to-end drug development expertise, from early stage (chemistry, formulation, preclinical) to advanced clinical stages and regulatory approvals.

The company was established in 2018 as a Spin-Off, with strong financial backing and a broad network.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
CLE-100
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Clexio Biosciences Ltd